In a relatively classic scenario, established technologies have seen a loss of their once-premium pricing while emerging technologies are able to command an increasing premium as reward for their sophistication. The worldwide coronary stent market is following the predicted course. Bare metal stents have been on the market for more than a decade and have, [...]
As an exercise, I found it worthwhile to map out the various options available or under development for the treatment of coronary artery disease. We assess the emphasis of current, near-term and future possible options for treatment in the color-coded scheme: Bold, black: Current, dominant treatment options Green: Near term options with potential to gain [...]
Because of the invasive nature of cardiac surgery, medical therapy will always be the preferred treatment protocol favored by many clinicians. To that end, device and pharmaceutical manufacturers continue to explore methods of treating atherosclerosis that will render surgery unnecessary. For instance, researchers at the Medical University of Graz in Austria announced in February 2009 [...]
The global market for stents in the treatment coronary artery disease, while dominated by drug-eluting stents, continues to also be comprised of a diversity of stent technologies. The market is evolving steadily as manufacturers aggressively seek optimal anti-restenosis, characterized by the goal of low rates of repeat revascularization. As with many medical technologies, prices, availability [...]
PRLog (Press Release) – Sep 09, 2009 – The global market for coronary stents is owned largely by drug-eluting stents (DES), but the size of the patient pool, the drive for lowered cost, ever-increased efficacy and less trauma are spawning the development of multiple new technologies in coronary stents and competitive anti-restenosis technologies. The global [...]
Translation: Drug-eluting stents are to bare metal stents as bare metal stents were to percutaneous transluminal coronary angioplasty alone. In the September 1 post on the meta-analysis by researchers at Tuft Medical Center, we noted the overall findings in general terms of the value of drug-eluting stents compared to bare metal stents. It is worthwhile to [...]
The global coronary stent market faces continued growth, development and competition from a wide range of technology types and competitors. The market is detailed in a new report from MedMarket Diligence. FOR IMMEDIATE RELEASE PRLog (Press Release) – Aug 31, 2009 – Since the advent of coronary stents, followed by the emergence of drug eluting [...]
Treatment of acute coronary artery disease was first accomplished surgically via the coronary artery bypass graft procedure some 45 years ago, then by angioplasty 32 years ago and finally by stenting 23 years ago. Despite the evolution of treatment alternatives (which continue to evolve), CABG has represented a benchmark, if not gold standard, against which [...]
In a report published in MedLink Neurology, Dr. Jose Biller of Loyola University Chicago’s Stritch School of Medicine completed a comprehensive review and compilation of previously published clinical studies on the possible neurological complications of heart surgery (Neurological complications of heart surgery). A range of difference potential complications have long been known to be attributable to heart [...]
The August 24, 2009, issue of the "Journal of the American Academy of Physician Assistants" presents a concise, yet accurately detailed view of the full context — coronary heart disease, clinical practice, demographics, complications, etc. — for the use of drug-eluting coronary stents. Having focused on drug-eluting stents (DES) from the product market analysis, I [...]
Contact:
